Bionano Genomics Highlights Three New Independently Authored, Peer-Reviewed Publications Showing Clinical Utility Of OGM In High-Risk Hematologic Malignancies
Bionano Genomics, Inc. (NASDAQ:BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk hematologic malignancies — myelodysplastic
Scientists published new studies showing Bionano's cancer test works well. When independent experts prove a medical tool is useful, it hints the company may gain more customers.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.